Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P392 - ESOC25-2475 UNLOCKING SHORT-TERM DUAL ANTIPLATELET THERAPYS POTENTIAL: SAFETY AND EFFECTIVENESS IN LARGE ARTERY ATHEROSCLEROSIS INSIGHTS FROM THE READAPT STUDY Federico De Santis 1 , Eleonora De Matteis 1,2 , Matteo Foschi 1 , Michele Romoli 3 , Tiziana Tassinari 4 , Valentina Saia 4 , Silvia Cenciarelli 5 , Chiara Padiglioni 5 , Bruno Censori 6 , Luisa Vinciguerra 6 , Maria Guarino 7 , Marialuisa Zedde 8 , Marina Diomedi 9 , Marco Petruzzellis 10 , Danilo Toni 11 , Stefano Ricci 5 , Simona Sacco 1 , Raffaele Ornello 1 1 Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy, 2 Department of Brain Sciences, Imperial College London, London, United Kingdom, 3 Stroke Unit, Maurizio Bufalini Hospital, Cesena, Italy, 4 Department of Neurology, Santa Corona Hospital, Pietra Ligure, Italy, 5 Department of Neurology, Citt di Castello Hospital, Citt di Castello, Italy, 6 Department of Neurology, ASST Cremona Hospital, Cremona, Italy, 7 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, 8 Department of Neurology, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 9 Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy, 10 Department of Neurology and Stroke Unit, F
CAVERJECT contains alprostadil, a synthetic form of prostaglandin E1 (PGE1), and is designated chemically as (11,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
That data includes: SMPT server name of the internet service provider Recipients email address Senders email address The content of the email If the email addresses are from the same domain, the same SMTP server can route mail directly on the same network to the recipients domain
In brief, T cells derived from patients are primed by genetic manipulation to target and remove cells that express a specific antigen
GSH depletion has been identified as an early-stage event in the pathogenesis of Parkinson's disease, occurring before the loss of dopaminergic neurons becomes clinically apparent
For many, thats the missing piece
